ProCE Banner Activity

Expert Commentary on the Use of IL-13 Inhibition in Treating Moderate to Severe Atopic Dermatitis

Clinical Thought

In this commentary, Dr Jonathan Silverberg provides insights on incorporating IL-13 inhibitors into the treatment algorithm for moderate to severe atopic dermatitis.

Released: May 19, 2023

Share

Faculty

Jonathan Silverberg

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly